Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: Results of a phase I study

Franco Di Filippo, Carlo R. Rossi, Maurizio Vaglini, Alberto Azzarelli, Michele Anzà, Mario Santinami, Mario Lise, Francesco Cavaliere, Diana Giannarelli, Vittorio Quagliuolo, Antonella Vecchiato, Marcello Deraco, Rosa Garinei, Maria Foletto, Claudio Botti, Renato Cavaliere

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

To improve the therapeutic effectiveness of hyperthermic antiblastic perfusion (HAP), the association of recombinant tumor necrosis factor alpha (rTNFα), doxorubicin, and true hyperthermia (41°C) was employed for the treatment of soft tissue limb sarcoma. A dose-escalation study according to Fibonacci's modified scheme was conducted, starting with a rTNFα dose of 0.5-3.3 mg. The doxorubicin doses (0.7 and 1.4 mg for the upper and lower limbs, respectively) and temperature level (41°C) remained unchanged. Eighteen patients have been treated thus far: 9 males and 9 females of a mean age of 33 years (range: 24-71 years). The tumor was located in the upper limb in one patient and in the lower limbs in seventeen. Only 16 patients were evaluable, as 2 refused further treatment after the perfusion. In terms of local toxicity, a grade I limb reaction was observed in 3 patients, a grade II or III in 10 patients, and a grade IV in 5 patients, showing a strict correlation between the TNF dose and the grade of limb reaction. In fact, a grade III-IV limb reaction was observed in 66.6% of the patients treated with >1 mg of rTNFα. The maximum tolerable dose in association with doxorubicin and true hyperthermia (41°C) was 2.4 mg. Eleven patients showed a good pathological response (>75%) and five patients showed a partial response (>25%-

Original languageEnglish
Pages (from-to)407-414
Number of pages8
JournalJournal of Immunotherapy
Volume22
Issue number5
Publication statusPublished - 1999

Fingerprint

Amputation
Sarcoma
Doxorubicin
Extremities
Tumor Necrosis Factor-alpha
Perfusion
Therapeutics
Lower Extremity
Fever
Upper Extremity
Temperature

Keywords

  • Doxorubicin
  • Perfusion
  • rTNFα
  • Soft tissue limb sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Immunology

Cite this

Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation : Results of a phase I study. / Di Filippo, Franco; Rossi, Carlo R.; Vaglini, Maurizio; Azzarelli, Alberto; Anzà, Michele; Santinami, Mario; Lise, Mario; Cavaliere, Francesco; Giannarelli, Diana; Quagliuolo, Vittorio; Vecchiato, Antonella; Deraco, Marcello; Garinei, Rosa; Foletto, Maria; Botti, Claudio; Cavaliere, Renato.

In: Journal of Immunotherapy, Vol. 22, No. 5, 1999, p. 407-414.

Research output: Contribution to journalArticle

Di Filippo, Franco ; Rossi, Carlo R. ; Vaglini, Maurizio ; Azzarelli, Alberto ; Anzà, Michele ; Santinami, Mario ; Lise, Mario ; Cavaliere, Francesco ; Giannarelli, Diana ; Quagliuolo, Vittorio ; Vecchiato, Antonella ; Deraco, Marcello ; Garinei, Rosa ; Foletto, Maria ; Botti, Claudio ; Cavaliere, Renato. / Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation : Results of a phase I study. In: Journal of Immunotherapy. 1999 ; Vol. 22, No. 5. pp. 407-414.
@article{fed3f936f5e44eee85185889a999b78b,
title = "Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: Results of a phase I study",
abstract = "To improve the therapeutic effectiveness of hyperthermic antiblastic perfusion (HAP), the association of recombinant tumor necrosis factor alpha (rTNFα), doxorubicin, and true hyperthermia (41°C) was employed for the treatment of soft tissue limb sarcoma. A dose-escalation study according to Fibonacci's modified scheme was conducted, starting with a rTNFα dose of 0.5-3.3 mg. The doxorubicin doses (0.7 and 1.4 mg for the upper and lower limbs, respectively) and temperature level (41°C) remained unchanged. Eighteen patients have been treated thus far: 9 males and 9 females of a mean age of 33 years (range: 24-71 years). The tumor was located in the upper limb in one patient and in the lower limbs in seventeen. Only 16 patients were evaluable, as 2 refused further treatment after the perfusion. In terms of local toxicity, a grade I limb reaction was observed in 3 patients, a grade II or III in 10 patients, and a grade IV in 5 patients, showing a strict correlation between the TNF dose and the grade of limb reaction. In fact, a grade III-IV limb reaction was observed in 66.6{\%} of the patients treated with >1 mg of rTNFα. The maximum tolerable dose in association with doxorubicin and true hyperthermia (41°C) was 2.4 mg. Eleven patients showed a good pathological response (>75{\%}) and five patients showed a partial response (>25{\%}-",
keywords = "Doxorubicin, Perfusion, rTNFα, Soft tissue limb sarcoma",
author = "{Di Filippo}, Franco and Rossi, {Carlo R.} and Maurizio Vaglini and Alberto Azzarelli and Michele Anz{\`a} and Mario Santinami and Mario Lise and Francesco Cavaliere and Diana Giannarelli and Vittorio Quagliuolo and Antonella Vecchiato and Marcello Deraco and Rosa Garinei and Maria Foletto and Claudio Botti and Renato Cavaliere",
year = "1999",
language = "English",
volume = "22",
pages = "407--414",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation

T2 - Results of a phase I study

AU - Di Filippo, Franco

AU - Rossi, Carlo R.

AU - Vaglini, Maurizio

AU - Azzarelli, Alberto

AU - Anzà, Michele

AU - Santinami, Mario

AU - Lise, Mario

AU - Cavaliere, Francesco

AU - Giannarelli, Diana

AU - Quagliuolo, Vittorio

AU - Vecchiato, Antonella

AU - Deraco, Marcello

AU - Garinei, Rosa

AU - Foletto, Maria

AU - Botti, Claudio

AU - Cavaliere, Renato

PY - 1999

Y1 - 1999

N2 - To improve the therapeutic effectiveness of hyperthermic antiblastic perfusion (HAP), the association of recombinant tumor necrosis factor alpha (rTNFα), doxorubicin, and true hyperthermia (41°C) was employed for the treatment of soft tissue limb sarcoma. A dose-escalation study according to Fibonacci's modified scheme was conducted, starting with a rTNFα dose of 0.5-3.3 mg. The doxorubicin doses (0.7 and 1.4 mg for the upper and lower limbs, respectively) and temperature level (41°C) remained unchanged. Eighteen patients have been treated thus far: 9 males and 9 females of a mean age of 33 years (range: 24-71 years). The tumor was located in the upper limb in one patient and in the lower limbs in seventeen. Only 16 patients were evaluable, as 2 refused further treatment after the perfusion. In terms of local toxicity, a grade I limb reaction was observed in 3 patients, a grade II or III in 10 patients, and a grade IV in 5 patients, showing a strict correlation between the TNF dose and the grade of limb reaction. In fact, a grade III-IV limb reaction was observed in 66.6% of the patients treated with >1 mg of rTNFα. The maximum tolerable dose in association with doxorubicin and true hyperthermia (41°C) was 2.4 mg. Eleven patients showed a good pathological response (>75%) and five patients showed a partial response (>25%-

AB - To improve the therapeutic effectiveness of hyperthermic antiblastic perfusion (HAP), the association of recombinant tumor necrosis factor alpha (rTNFα), doxorubicin, and true hyperthermia (41°C) was employed for the treatment of soft tissue limb sarcoma. A dose-escalation study according to Fibonacci's modified scheme was conducted, starting with a rTNFα dose of 0.5-3.3 mg. The doxorubicin doses (0.7 and 1.4 mg for the upper and lower limbs, respectively) and temperature level (41°C) remained unchanged. Eighteen patients have been treated thus far: 9 males and 9 females of a mean age of 33 years (range: 24-71 years). The tumor was located in the upper limb in one patient and in the lower limbs in seventeen. Only 16 patients were evaluable, as 2 refused further treatment after the perfusion. In terms of local toxicity, a grade I limb reaction was observed in 3 patients, a grade II or III in 10 patients, and a grade IV in 5 patients, showing a strict correlation between the TNF dose and the grade of limb reaction. In fact, a grade III-IV limb reaction was observed in 66.6% of the patients treated with >1 mg of rTNFα. The maximum tolerable dose in association with doxorubicin and true hyperthermia (41°C) was 2.4 mg. Eleven patients showed a good pathological response (>75%) and five patients showed a partial response (>25%-

KW - Doxorubicin

KW - Perfusion

KW - rTNFα

KW - Soft tissue limb sarcoma

UR - http://www.scopus.com/inward/record.url?scp=0032849248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032849248&partnerID=8YFLogxK

M3 - Article

C2 - 10546156

AN - SCOPUS:0032849248

VL - 22

SP - 407

EP - 414

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 5

ER -